Anick Bérard

Dr. Anick Bérard

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
TBTakoua Boukhris
Takoua Boukhris
OSOdile Sheehy
Odile Sheehy
LMLaurent Mottron
Laurent Mottron
ABAnick Bérard
Anick Bérard
Quiz Ref ID Antidepressants (ADs) are widely used during gestation for the treatment of depression. In the United States, the prevalence of AD use during pregnancy increased from 5.7% in 1999 to 13.3% in 20031; in Canada, 4.5% of pregnant women reported using ADs between 2001 and 2006.2 However, there is continued confusion regarding the appropriate use of ADs during this critical period. Gestational exposure to ADs has been associated with an increased risk of spontaneous abortion,3 major congenital malformations,4 prematurity,5,6 low birth weight,5,6 neonatal withdrawal,7 and pregnancy-induced hypertension.8 Discontinuation of ADs during pregnancy in women with severe depression was associated with relapse in some studies.9 Nevertheless, up to 20% of women who continue to use ADs during pregnancy remain depressed,10 suggesting a lack of efficacy in some pregnant women.

22 December 2006 in Birth Defects Research Part B: Developmental and Reproductive Toxicology
Verified
Journal Article
Closed access
PDF file
ABAnick Bérard
Anick Bérard
ÉRÉlodie Ramos
Élodie Ramos
ÉRÉvelyne Rey
Évelyne Rey
LBLucie Blais
Lucie Blais
MSMartin St.‐André
Martin St.‐André
DODriss Oraichi
Driss Oraichi

17 April 2012 in Research in Nursing & Health
Verified
Journal Article
Closed access
PDF file
FKFatiha Karam
Fatiha Karam
ABAnick Bérard
Anick Bérard
OSOdile Sheehy
Odile Sheehy
MHMarie‐Claude Huneau
Marie‐Claude Huneau
GBGerald Briggs
Gerald Briggs
TCthe OTIS Research Committee
the OTIS Research Committee

6 September 2011 in Canadian Medical Association Journal
Verified
Journal Article
Open access
PDF file
HNHamid Reza Nakhai-Pour
Hamid Reza Nakhai-Pour
PBPerrine Broy
Perrine Broy
OSOdile Sheehy
Odile Sheehy
ABAnick Bérard
Anick Bérard
Background: The association between the use of nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) during pregnancy and the risk of spontaneous abortion remains unclear because of inconsistent research results and the lack of evidence for an effect due to specific types or dosages of nonaspirin NSAIDs. We aimed to quantify the association between having a spontaneous abortion and types and dosages of nonaspirin NSAIDs in a cohort of pregnant women. Methods: Using a nested case–control design, we obtained data from the Quebec Pregnancy Registry for 4705 women who had a spontaneous abortion. For each instance, we randomly selected 10 controls from the remaining women in the registry who were matched by index date (date of the spontaneous abortion) and gestational age. Use of nonaspirin NSAIDs (identified by filled prescriptions) and nonuse were compared. We also looked for associations between different types and dosages of nonaspirin NSAIDs and having a spontaneous abortion. Analyses of associations and adjustment for confounding were done using conditional logistic regression. Results: We identified 4705 cases of spontaneous abortion (352 exposed [7.5%]); 47 050 controls (1213 exposed [2.6%]). Adjusting for potential confounders, the use of nonaspirin NSAIDs during pregnancy was significantly associated with the risk of spontaneous abortion (odds ratio [OR] 2.43, 95% confidence interval [CI] 2.12–2.79). Specifically, use of diclofenac (OR 3.09, 95% CI 1.96–4.87), naproxen (OR 2.64, 95% CI 2.13–3.28), celecoxib (OR 2.21, 95% CI 1.42–3.45), ibuprofen (OR 2.19, 95% CI 1.61–2.96) and rofecoxib (OR 1.83, 95% CI 1.24–2.70) alone, and combinations thereof (OR 2.64, 95% CI 1.59–4.39), were all associated with increased risk of spontaneous abortion. No dose–response effect was seen. Interpretation: Gestational exposure to any type or dosage of nonaspirin NSAIDs may increase the risk of spontaneous abortion. These drugs should be used with caution during pregnancy

31 May 2010 in Canadian Medical Association Journal
Verified
Journal Article
Closed access
PDF file
HNHamid Reza Nakhai-Pour
Hamid Reza Nakhai-Pour
PBPerrine Broy
Perrine Broy
ABAnick Bérard
Anick Bérard
Background: The risk of relapse of depression or the diagnosis of some other psychiatric disorders during pregnancy necessitates the use of antidepressants despite possible adverse effects. Whether such use increases the risk of spontaneous abortion is still being debated. We evaluated the risk of spontaneous abortion in relation to the use of antidepressants during pregnancy. Methods: Using a nested case–control study design, we obtained data from the Quebec Pregnancy Registry for 5124 women who had a clinically detected spontaneous abortion. For each case, we randomly selected 10 controls from the remaining women in the registry who were matched by the case’s index date (date of spontaneous abortion) and gestational age at the time of spontaneous abortion. Use of antidepressants was defined by filled prescriptions and was compared with nonuse. We also studied the classes, types and doses of antidepressants. Results: A total of 284 (5.5%) of the women who had a spontaneous abortion had at least one prescription for an antidepressant filled during the pregnancy, as compared with 1401 (2.7%) of the matched controls (odds ratio [OR] 2.09, 95% confidence interval [CI] 1.83–2.38). After adjustment for potential confounders, we found that the use of antidepressants during pregnancy was associated with an increased risk of spontaneous abortion (OR 1.68, 95%CI 1.38–2.06). Stratified analyses showed that use of selective serotonin reuptake inhibitors alone (OR 1.61, 95% CI 1.28–2.04), serotonin–norepinephrine reuptake inhibitors alone (OR 2.11, 95% CI 1.34–3.30) and combined use of antide-pressants from different classes (OR 3.51, 95% CI 2.20–5.61) were associated with an increased risk of spontaneous abortion. When we looked at antidepressant use by type versus no use, paroxetine use alone (OR 1.75, 95% CI 1.31–2.34) and venlafaxine use alone (OR 2.11, 95% CI 1.34–3.30) were associated with an increased risk of spontaneous abortion. Interpretation: The use of antidepressants, especially paroxetine, venlafaxine or the combined use of different classes of antidepressants, during pregnancy was associated with an increased risk of spontaneous abortion.

13 October 2008 in BJOG: An International Journal of Obstetrics & Gynaecology
Verified
Journal Article
Open access
PDF file
ALA Lacasse
A Lacasse
ERE Rey
E Rey
EFE Ferreira
E Ferreira
CMC Morin
C Morin
ABAnick Bérard
Anick Bérard
Objective  The objective of this study was to determine the impact of nausea and vomiting of pregnancy (NVP) and other determinants on generic and NVP‐specific health‐related quality of life (QOL) in the first trimester of pregnancy.Design  Prospective study.Setting  Centre Hospitalier Universitaire (CHU) Sainte‐Justine or René‐Laennec clinics, Montreal, Quebec, Canada.Population  Pregnant women attending the clinics for their prenatal care from 2004 to 2006. Women were eligible if they were ≥18 years of age and ≤16 weeks of gestation at the time of their first prenatal visit.Methods  After their first prenatal visit, women were asked to fill out a questionnaire covering maternal characteristics, presence and severity of NVP, and health‐related QOL.Main outcome measures  QOL was measured by the generic 12‐item Short Form Health Survey v.1 (SF‐12) and the NVP‐specific Quality of Life for Nausea and Vomiting during Pregnancy.Results  Of the 367 pregnant women included in the study, 78.5% of women reported NVP in the first trimester of pregnancy. Multivariable linear models showed that presence of NVP in the first trimester of pregnancy was significantly associated with a lower physical component summary scale (P < 0.0001) and mental component summary scale (P = 0.0066) of the SF‐12 scores. More severe NVP (moderate versus mild: P = 0.0002; severe versus mild: P = 0.0177 as measured by the validated modified Pregnancy‐Unique Quantification of Emesis and Nausea index), intensity of nausea symptoms reported on a visual analogue scale (P < 0.0001), and nonpharmacological methods used to ease NVP symptoms in the first trimester of pregnancy (P = 0.0059) were significantly associated with poorer NVP‐specific QOL among women suffering from NVP.Conclusion  These findings show that presence and severity of NVP have a negative impact on health‐related QOL, which emphasises the importance of an optimal management of NVP.